# Junta clínica — PT-pseudo_47c373e230b6 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_47c373e230b6",
  "pid": "PT-pseudo_47c373e230b6",
  "task": 1,
  "psa": 10.0,
  "age": 75,
  "months": 1,
  "pirads": "5",
  "psad": 0.27,
  "psav": 1.78,
  "psap": 8.3,
  "vol": 41.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.7478973,
  "medhx": "Hypertension, Hypercholesterolaemia, Benign prostatic hyperplasia",
  "meds": "amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, tamsulosin",
  "notes": "PSA 10 ng/mL. PI-RADS 5. PSAD 0.27. Prostate volume 41 mL. csPCa 0.75.",
  "pmhx": [
    "Hypertension",
    "Hypercholesterolaemia",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "66 kg",
    "height": "180 cm",
    "bmi": "20.4",
    "bp": "122/66 mmHg",
    "hr": "73 bpm",
    "smoking": "Ex-smoker (18 pack-yr, quit 2006)",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "09 Feb 2025",
  "enc_ref": "Dr. P. van Dijk (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ascending prostate-specific antigen readings and a history of a previously positive biopsy prompt this clinical assessment."
    },
    {
      "s": "History",
      "t": "A 75-year-old male, formerly employed as a warehouse manager, first entered the diagnostic pathway in late 2022 due to an elevated prostate-specific antigen level. His medical background includes hypertension and hypercholesterolaemia, alongside benign prostatic hyperplasia. Current pharmacotherapy comprises amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, and tamsulosin to address bothersome lower urinary tract symptoms. Tobacco use ceased in 2006 after an 18 pack-year accumulation. He continues a weekly swimming regimen. Although widowed, he resides with his partner who offers daily assistance, while his adult children stop by each week to manage paperwork. Recent visits to ophthalmology for cataract surveillance and a standard chest radiograph returned normal results. He denies experiencing fresh urinary blockage, blood in the urine, or skeletal discomfort, maintaining a stable International Prostate Symptom Score of 12."
    },
    {
      "s": "Physical examination",
      "t": "Normal DRE: The gland demonstrates a smooth, firm consistency with symmetric enlargement and no palpable irregularities. Vital parameters remain stable: blood pressure registers at 122/66 mmHg with a regular cardiac rhythm of 73 bpm. General survey shows a well-nourished individual free of acute distress. Lung fields are clear, and abdominal palpation reveals a soft, non-tender contour."
    }
  ],
  "occupation": "warehouse manager",
  "marital": "Widowed",
  "living": "Lives with partner; adult children visit weekly",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Ophthalmology — cataract review",
    "Radiology — chest X-ray (routine)"
  ],
  "alcohol": "12 units / week",
  "exercise": "Swimming 1x/week",
  "ipss": "IPSS score: 12/35 (moderate LUTS)",
  "admin": "Daughter manages communication; CC on letters with patient consent.",
  "mri_hospital": "Antoni van Leeuwenhoek",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_47c373e230b6
Task: 1

Encounter: Urology - outpatient on 09 Feb 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 75-year-old male
  - PSA: 10.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.27 ng/mL²
  - PSA velocity: 1.78 ng/mL/yr
  - Prior PSA: 8.3 ng/mL
  - Prostate volume: 41.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7478973 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia, Benign prostatic hyperplasia
  - Current medication: amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 10 ng/mL. PI-RADS 5. PSAD 0.27. Prostate volume 41 mL. csPCa 0.75.

Vitals: weight 66 kg, height 180 cm, BMI 20.4, BP 122/66 mmHg, HR 73 bpm. Smoking: Ex-smoker (18 pack-yr, quit 2006).

Chief complaint: Ascending prostate-specific antigen readings and a history of a previously positive biopsy prompt this clinical assessment.

History: A 75-year-old male, formerly employed as a warehouse manager, first entered the diagnostic pathway in late 2022 due to an elevated prostate-specific antigen level. His medical background includes hypertension and hypercholesterolaemia, alongside benign prostatic hyperplasia. Current pharmacotherapy comprises amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, and tamsulosin to address bothersome lower urinary tract symptoms. Tobacco use ceased in 2006 after an 18 pack-year accumulation. He continues a weekly swimming regimen. Although widowed, he resides with his partner who offers daily assistance, while his adult children stop by each week to manage paperwork. Recent visits to ophthalmology for cataract surveillance and a standard chest radiograph returned normal results. He denies experiencing fresh urinary blockage, blood in the urine, or skeletal discomfort, maintaining a stable International Prostate Symptom Score of 12.

Physical examination: Normal DRE: The gland demonstrates a smooth, firm consistency with symmetric enlargement and no palpable irregularities. Vital parameters remain stable: blood pressure registers at 122/66 mmHg with a regular cardiac rhythm of 73 bpm. General survey shows a well-nourished individual free of acute distress. Lung fields are clear, and abdominal palpation reveals a soft, non-tender contour.

Patient info: warehouse manager; Widowed; Lives with partner; adult children visit weekly.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 12 units / week; exercise Swimming 1x/week; IPSS score: 12/35 (moderate LUTS).

Recent other appointments: Ophthalmology — cataract review; Radiology — chest X-ray (routine).
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.63
  uncertainty  +/- 0.11 epistemic (95% band 0.42-0.84); among patients I cannot tell apart the outcome was 0.95 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.63: PI-RADS 5, PSA 10.0, PSAD 0.372, age 75, DRE Normal -> BIOPSY (clear). He wrote: "Intermediate risk disease in 75yr with some comorbidity. No targeted biopsy and unclear timing (when was diagnosis and prev biopsy). Unclear if PIRADS5 was biopsied (lim…"
  2. distance 1.26: PI-RADS 5, PSA 5.5, PSAD 0.12, age 71, DRE Normal -> BIOPSY (clear). He wrote: "Prev biopsy finding is left lobe, MRI finding highly suspicious of ISUP≥2 on right side. Active surveillance, only 1 biopsy session performed (of unclear date and unclea…"
  3. distance 1.27: PI-RADS 5, PSA 9.3, PSAD 0.516, age 71, DRE Normal -> DEFER (clear). He wrote: "He has a ISUP3 cancer diagnosis already and he should be recommended treatment"

PRECEDENT: BIOPSY (weighted vote 0.75 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI mandates a repeat biopsy to confirm histological progression before a change in treatment strategy. A stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not decisive because the guideline makes the decision based on the MRI findings and the stability of the PSA density, which are not fully addressed by the panel variables alone. The precedent cited by Expert 5 shows that the decision in similar cases was not clear, suggesting that the prior biopsy status alone is insufficient to guide the current action.

WHAT WE STILL NEED
The prior biopsy status is documented as "Positive" on the panel, which is a fact that the guideline makes it decide. The panel shows a PI-RADS score of 5 and a PSA of 10.0 ng/mL, which are values that the guideline makes it decide. The previous notes are where the grade of the prior biopsy and the number and dates of biopsy sessions and whether he is on a surveillance protocol with a confirmatory biopsy due.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges entirely on the documented grade and surveillance status from the previous biopsy notes, as the panel variables alone are insufficient.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What is the management context, including the prior biopsy grade (Gleason/ISUP), number and dates of biopsy sessions, and surveillance protocol status?
  laboratory_results (get_lab_results) -> What are the full panel results, including free-PSA fraction, renal function, and hemoglobin?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the grade (Gleason or ISUP) of the prior biopsy?
  Q2. How many biopsy sessions were performed and when were they conducted?
  Q3. Is the patient currently on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Prostate Multiparametric MRI | 05 February 2025 | Dept. of Radiology
Lesion size and zone: A discrete 14 mm focus occupies the left mid-gland peripheral zone.
Extraprostatic extension: The capsule remains intact without seminal vesicle encroachment.
Comparison against an earlier study: new
psa_trend
Serial PSA value trend: Rising, with values at "Nov 2022" of "9.1" ng/mL, "Aug 2023" of "2.8" ng/mL, "May 2024" of "6.3" ng/mL, and "Feb 2025" of "10.0" ng/mL.
previous_notes
Management context, including the prior biopsy grade (Gleason/ISUP), number and dates of biopsy sessions, and surveillance protocol status: Prior biopsy finding is "low-grade disease", number of biopsy sessions is not explicitly stated, and surveillance protocol status is "routine PSA tracking and yearly check-ups".
laboratory_results
Full panel results, including free-PSA fraction, renal function, and hemoglobin: PSA is "10.0 ng/mL", Free PSA is "1.65 ng/mL", %Free PSA is "16%", Creatinine is "106 umol/L", and Hemoglobin is "15.6 g/dL".

WHAT I DID NOT OPEN
family-history of prostate cancer (anamnesis) because the previous notes provided sufficient context regarding the prior biopsy.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 5 designation applies to the left mid-gland peripheral zone abnormality.
Serial PSA value trend is rising, with the most recent value being "10.0 ng/mL".

Findings that argue AGAINST sampling this patient now:
Prior biopsy finding is "low-grade disease".
The patient is on a "routine PSA tracking and yearly check-ups" surveillance protocol.

WHERE THIS LEANS
The findings suggest a need for further clarification given the PI-RADS 5 and rising PSA, but the prior low-grade biopsy result and routine surveillance protocol temper the urgency.
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 10.00 ng/mL over 4 points spanning 27 months; velocity +0.83 ng/mL per year; doubling time about 57 months.
PROJECTION at 6 months: 17.0 ng/mL, conformal 95% band 4.9-59.1.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.64
  uncertainty  +/- 0.10 epistemic (95% band 0.43-0.84), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.63  ('supports' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.64  ('supports' tier, fusion_full)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.75  (k=3 precedents)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.64 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('supports' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—directly address all three moderator questions by providing information on the lesion, PSA trend, management context including prior biopsy grade and surveillance status, and full lab panel results.

ALIGNMENT WITH THE PANEL
The panel protocol concluded with a BIOPSY recommendation based on a weighted vote of the experts, despite the lack of a documented prior grade in the opened documents. The retrieved information suggests a need for further clarification, as the previous notes indicated a "low-grade disease" and a "routine PSA tracking and yearly check-ups" protocol.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the grade (Gleason or ISUP) of the prior biopsy? Answered by previous_notes: "low-grade disease".
Q2. How many biopsy sessions were performed and when were they conducted? Answered by previous_notes: "number of biopsy sessions is not explicitly stated".
Q3. Is the patient currently on a surveillance protocol with a confirmatory biopsy due? Answered by previous_notes: "routine PSA tracking and yearly check-ups".

WHAT CARRIES WEIGHT, AND WHY
The most relevant variables for the EAU guideline are the documented prior biopsy grade and the surveillance protocol status, as these directly inform the decision regarding repeat biopsy necessity. The rising PSA trend and PI-RADS 5 are important but are tempered by the prior low-grade finding and routine surveillance.

MY SUGGESTION TO THE CHAIR
Given that the prior biopsy was documented as "low-grade disease" and the patient is on a "routine PSA tracking and yearly check-ups" protocol, the EAU guideline suggests that a stable MRI and low-risk features might exclude a repeat biopsy. Therefore, I suggest deferring the immediate biopsy and continuing the routine surveillance, pending further clinical correlation.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

A biopsy is recommended because the patient presents with a PI-RADS 5 finding and a rising PSA trend, which are significant factors. This decision is supported by the fusion classifier's high probability and the weighted vote of the experts. The clinical context, including the prior positive biopsy and the patient's age of 75, indicates that further histological clarification is warranted despite the routine surveillance protocol.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
